Current:Home > StocksWhy does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers. -ValueCore
Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
View
Date:2025-04-11 16:09:25
Senators grilled the top executive of Novo Nordisk over why the Danish company charges Americans far more for the blockbuster weight-loss drug Wegovy and diabetes drug Ozempic than it does patients in Europe.
Novo Nordisk CEO Lars Fruergaard Jørgensen appeared before the Senate Committee on Health, Education, Labor and Pensions. The committee is chaired by Sen. Bernie Sanders, a Vermont independent who launched an investigation this year into Novo Nordisk's drug pricing.
Novo Nordisk has made nearly $50 billion on the sales of Ozempic and Wegovy since 2018, Sanders said. He described the U.S. as a "cash cow" for Novo Nordisk, accounting for 72% of the company's worldwide sales of those two drugs.
Among questions posed by Sanders: Why do Americans pay far more for these medications than patients in other countries?
Sanders opened the hearing by displaying charts comparing Novo Nordisk's prices charged to Americans and Europeans. The company charges U.S. residents $969 a month for Ozempic, but the same drug costs $155 in Canada, $122 in Denmark, and $59 in Germany.
For the weight-loss drug Wegovy, Americans pay $1,349 a month. The drug can be purchased for $186 in Denmark, $140 in Germany, and $92 in the United Kingdom, according to Sanders' charts.
"Nobody here is asking Novo Nordisk to provide charity to the American people," Sanders said. "All we are saying, Mr. Jørgensen, is treat the American people the same way that you treat people all over the world. Stop ripping us off."
Jørgensen defended the company's pricing of the wildly popular medications and said 80% of Americans can get these drugs for $25 or less per month.
He said U.S. list prices can't be compared to prices charged in other countries, in part, due to the nation's complex structure. U.S. prices are influenced by health insurance companies and drug-pricing middlemen called pharmacy benefit managers.
Jørgensen said the diabetes drug Ozempic is covered by the vast majority of private health insurance plans, as well as Medicare and Medicaid, the government health insurance programs for seniors and low-income families. Wegovy is covered by about half of private health insurers, Medicaid plans in 20 states and the Department of Veterans Affairs.
"You have said that our amazing medicines can't help patients if they can't afford them ‒ that is true," Jørgensen said. "It is also true that the full value of Ozempic and Wegovy can only be realized if patients can access them. Patients need affordability and access."
Medicare, the federal health program for adults 65 and older, is prohibited by law from covering drugs for those who are obese but otherwise do not have serious risk factors. But obese patients with diabetes or heart disease may qualify for coverage. The nonprofit health policy organization KFF estimated that 1 in 4 Medicare enrollees who are obese may be eligible for Wegovy to reduce their risk of heart attack or stroke.
The committee also highlighted a March study from researchers at Yale University found these drugs could be made for less than $5 a month, or $57 per year. Last week, Sanders announced CEOs of major generic pharmaceutical companies would be willing to sell Ozempic to Americans for less than $100 per month, at a profit. However, such estimates do not account for the expensive costs of researching and developing drugs and testing them in clinical trials.
Jørgensen said Novo Nordisk scientists have worked on the weight-loss drugs since the early 1990s. The company also has committed $30 billion to expand manufacturing capacity to address supply shortages of the medications.
Representatives of drug industry's trade group PhRMA said health insurers and pharmacy benefit managers deserve more scrutiny when it comes to drug affordability.
“The one question everyone should be asking is why aren’t insurers and PBMs being forced to answer for denying coverage and driving up patients’ costs?" said Alex Schriver, senior vice president of public affairs at PhRMA: "Senator Sanders continues repeating the same misleading rhetoric on drug prices. But why won’t he talk about how insurance conglomerates are taking in record profits or how PBMs are being investigated and sued for their abusive tactics?"
veryGood! (957)
Related
- Most popular books of the week: See what topped USA TODAY's bestselling books list
- Bohannan requests a recount in Iowa’s close congressional race as GOP wins control of House
- NBA today: Injuries pile up, Mavericks are on a skid, Nuggets return to form
- KFC sues Church's Chicken over 'original recipe' fried chicken branding
- North Carolina trustees approve Bill Belichick’s deal ahead of introductory news conference
- High-scoring night in NBA: Giannis Antetokounmpo explodes for 59, Victor Wembanyama for 50
- Golden Bachelorette: Joan Vassos Gets Engaged During Season Finale
- After years of unrest, Commanders have reinvented their culture and shattered expectations
- North Carolina justices rule for restaurants in COVID
- 5-year-old boy who went missing while parent was napping is found dead near Oregon home, officials say
Ranking
- North Carolina justices rule for restaurants in COVID
- FBI raids New York City apartment of Polymarket CEO Shayne Coplan, reports say
- Powell says Fed will likely cut rates cautiously given persistent inflation pressures
- Man who stole and laundered roughly $1B in bitcoin is sentenced to 5 years in prison
- Man can't find second winning lottery ticket, sues over $394 million jackpot, lawsuit says
- Satire publication The Onion acquires Alex Jones' Infowars at auction
- The state that cleared the way for sports gambling now may ban ‘prop’ bets on college athletes
- Florida State can't afford to fire Mike Norvell -- and can't afford to keep him
Recommendation
Nevada attorney general revives 2020 fake electors case
Padma Lakshmi, John Boyega, Hunter Schafer star in Pirelli's 2025 calendar: See the photos
What is best start in NBA history? Five teams ahead of Cavaliers' 13-0 record
New Orleans marks with parade the 64th anniversary of 4 little girls integrating city schools
Who's hosting 'Saturday Night Live' tonight? Musical guest, how to watch Dec. 14 episode
FBI raids New York City apartment of Polymarket CEO Shayne Coplan, reports say
Only 8 monkeys remain free after more than a week outside a South Carolina compound
Tesla issues 6th Cybertruck recall this year, with over 2,400 vehicles affected